Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is United Laboratories International Holdings Median PS Value?
United Laboratories International HoldingsULIHF 80 Median PS Value is $1.11 as of Jul. 16, 2026, which is 16% above its 10-year median of 0.96. GuruFocus rates ULIHF with a GF Score™ of 80/100 and a GF Value™ of $1.43 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 544 Drug Manufacturers companies, United Laboratories International Holdings ranks worse than 67.83% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
ULIHF's Price-to-Median-PS-Value is ranked worse than 67.83% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.9
vs ULIHF: 1.12
United Laboratories International Holdings (OTCPK:ULIHF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
United Laboratories International Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.24
/
1.11
=
1.12
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Median PS Value Related Terms
United Laboratories International Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings Median PS Value Chart
United Laboratories International Holdings Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Laboratories International Holdings Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where United Laboratories International Holdings's Price-to-Median-PS-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Laboratories International Holdings (ULIHF) has a Median PS Value of $1.11 as of Jul. 16, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on United Laboratories International Holdings and its competitors. This is 16% above median its historical median of 0.96. Over the past decade, United Laboratories International Holdings' Median PS Value has ranged from 0.70 to 1.53. According to the industry distribution chart, United Laboratories International Holdings ranks #369 out of 544 companies in the Drug Manufacturers industry, placing it in the top 67.8%.
Is United Laboratories International Holdings' Median PS Value too high?
United Laboratories International Holdings' current Median PS Value of $1.11 is 16% above median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 1.53. The Drug Manufacturers industry median Median PS Value is 0.90. United Laboratories International Holdings' value of $1.11 is 23.3% above this industry median. Based on the distribution chart, United Laboratories International Holdings ranks #369 out of 544 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, United Laboratories International Holdings has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does United Laboratories International Holdings' Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, United Laboratories International Holdings ranks #369 out of 544 companies for Median PS Value. This places United Laboratories International Holdings in the lower half of its industry. The industry median Median PS Value is 0.90. United Laboratories International Holdings' value of $1.11 is 23.3% above this benchmark. Historically, United Laboratories International Holdings' own Median PS Value has ranged from 0.70 to 1.53 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 0.90, United Laboratories International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.90, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Laboratories International Holdings's current Median PS Value of $1.11 is 23.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on United Laboratories International Holdings and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Laboratories International Holdings's current Median PS Value is $1.11, which is 16% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Laboratories International Holdings stock overvalued right now?
Based on GuruFocus' analysis, United Laboratories International Holdings (ULIHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.43, compared to a current price of $1.24 — trading 13.3% below its estimated fair value. The current Median PS Value is $1.11, which is 16% above median its 10-year median of 0.96 and 23.3% above the Drug Manufacturers industry median of 0.90. United Laboratories International Holdings' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For United Laboratories International Holdings (ULIHF), the current Median PS Value is $1.11 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Laboratories International Holdings (ULIHF) Overvalued in 2026?
Based on GuruFocus' analysis, United Laboratories International Holdings stock appears to be undervalued.
The current stock price of $1.24 is trading 13.3% below its estimated GF Value™ of $1.43.
GuruFocus considers United Laboratories International Holdings to be Modestly Undervalued.
Key valuation signals for ULIHF:
Median PS Value: $1.11 (16% above median its 10-year median of 0.96)
GF Value™: $1.43 vs. price of $1.24 (13.3% below fair value)
Industry Position: 23.3% above the Drug Manufacturers median (#369 of 544)
No single metric tells the full story. See the ULIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Laboratories International Holdings Business Description
United Laboratories International Holdings Ltd is mainly engaged in the research and development, production and sales of pharmaceuticals. The company operates in three segments: Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Finished products segment, followed by Bulk medicine. The majority of the company's sales are generated in China, followed by Europe, India and other countries.
80GF Score
Get the complete analysis for ULIHF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ULIHF has been successfully added to your 
